Conformisreported 2Q20 orthopedic revenue of USD $19.5 million, -0.6% vs. 2Q19. Nearly half the company’s revenue for the quarter came from royalties paid by Zimmer Biomet in a settlement concerning patient-specific instrument patents. Conformis’ product revenue declined by -51.5% in the second quarter. The company remains on track to meet milestones for its patient-specific instrument supply agreement with Stryker. It estimates the deal could contribute $10 million to $20 million in annual revenue within five years.
To leverage the acceleration of ASCs, Conformis announced it will launch a line of knee replacements with standardized polyethylene inserts. The new implants will use the iView preplanning system as well as patient-specific instruments to provide a “knee in a box” with lower costs and shorter lead times compared to Conformis’ customized knees. The company expects to launch the new knee system in 2H21.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Joint Replacement Knees
$18.9
$19.1
($0.2)
(1%)
Joint Replacement Hips
$0.6
$0.5
$0.1
12%
Total
$19.5
$19.6
($0.1)
(0.6%)
1H20
1H19
$ Chg
% Chg
Joint Replacement Knees
$34.9
$39.2
($4.3)
(11%)
Joint Replacement Hips
$1.0
$1.0
$0.0
1.5%
Total
$35.9
$40.2
($4.3)
(10.7%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
US
$18.1
$17.5
$0.6
3.5%
OUS
$1.4
$2.1
($0.7)
(34.1%)
Total
$19.5
$19.6
($0.1)
(0.6%)
1H20
1H19
$ Chg
% Chg
US
$32.1
$35.2
($3.2)
(9%)
OUS
$3.9
$5.0
($1.1)
(22.7%)
Total
$35.9
$40.2
($4.3)
(10.7%)
Earnings
Amt
% of Sales
Sales
$19.5
Cost of Sales
$8.5
43.4%
Sales and Marketing
$4.1
21.1%
R & D
$2.7
14.1%
General and Admin
$6.5
33.3%
Other
($0.2)
(0.8%)
Net Earnings
($2.1)
(11%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Conformisreported 2Q20 orthopedic revenue of USD $19.5 million, -0.6% vs. 2Q19. Nearly half the company's revenue for the quarter came from royalties paid by Zimmer Biomet in a settlement concerning patient-specific instrument patents. Conformis' product revenue declined by -51.5% in the second quarter. The company remains on track to...
Conformisreported 2Q20 orthopedic revenue of USD $19.5 million, -0.6% vs. 2Q19. Nearly half the company’s revenue for the quarter came from royalties paid by Zimmer Biomet in a settlement concerning patient-specific instrument patents. Conformis’ product revenue declined by -51.5% in the second quarter. The company remains on track to meet milestones for its patient-specific instrument supply agreement with Stryker. It estimates the deal could contribute $10 million to $20 million in annual revenue within five years.
To leverage the acceleration of ASCs, Conformis announced it will launch a line of knee replacements with standardized polyethylene inserts. The new implants will use the iView preplanning system as well as patient-specific instruments to provide a “knee in a box” with lower costs and shorter lead times compared to Conformis’ customized knees. The company expects to launch the new knee system in 2H21.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Joint Replacement Knees
$18.9
$19.1
($0.2)
(1%)
Joint Replacement Hips
$0.6
$0.5
$0.1
12%
Total
$19.5
$19.6
($0.1)
(0.6%)
1H20
1H19
$ Chg
% Chg
Joint Replacement Knees
$34.9
$39.2
($4.3)
(11%)
Joint Replacement Hips
$1.0
$1.0
$0.0
1.5%
Total
$35.9
$40.2
($4.3)
(10.7%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
US
$18.1
$17.5
$0.6
3.5%
OUS
$1.4
$2.1
($0.7)
(34.1%)
Total
$19.5
$19.6
($0.1)
(0.6%)
1H20
1H19
$ Chg
% Chg
US
$32.1
$35.2
($3.2)
(9%)
OUS
$3.9
$5.0
($1.1)
(22.7%)
Total
$35.9
$40.2
($4.3)
(10.7%)
Earnings
Amt
% of Sales
Sales
$19.5
Cost of Sales
$8.5
43.4%
Sales and Marketing
$4.1
21.1%
R & D
$2.7
14.1%
General and Admin
$6.5
33.3%
Other
($0.2)
(0.8%)
Net Earnings
($2.1)
(11%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
